Presented at PepTalk, San Diego, CA, USA
Work on bispecific antibodies has exploded and more sophisticated engineering approaches are now used. Concurrently, increasing numbers of bispecific platforms (e.g., tandem-scFv-Fc, DVD-Ig, diabodies) and parametric variants (e.g., linkers, V-domain orientation, Fc) must be tested. We present latest advances in our workflow platform for in-format screening (e.g., fully automated molecule design, DNA synthesis, and verification) and platform-specific expression processes (e.g., post production exchange reactions). Integrated into a comprehensive data management system for samples, assays, and analytics results, the platform enables systematic evaluation of large panels of next-generation antibodies.